Skip to main content
Markets
/
CONCORDBIO · NSE
Market closedNSE | BSE
Loading live market indices
CO
NSE · Equity shares · Biotechnology & Drugs

Concord Biotech CONCORDBIO

NSE:INR 1,374.7Recorded price
BSE:INR 1,370Recorded price
Not available · Not available
Advanced chart
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceStale · last-known data
Company fundamentalsStale · last-known data
Research sections8 of 9 availableMissing source values remain unavailable, never zero-filled.
Snapshot

Price and key statistics

Reported and computed values remain separate; missing values are not converted to zero.

Previous closeData unavailable
Day rangeINR 1,370 — INR 1,411.15
52-week rangeINR 987.05 — INR 1,803.6
VolumeNot available
Market cap14,332.42
P/E48.66
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)1,054.89
Net Income (INR Cr)260.91
Rev Growth (5 Year %)11.32
EPS Growth (5 Year %)2.12
P/E Ratio48.66
EPS25.17

Research path: Interpret Concord Biotech's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.

AI and Advanced

AI analysis and Advanced tools for CONCORDBIO

Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.

AI analysisReview the complete evidence-led AI research workflow.Generate reportCreate a versioned report with entitlement and credit checks.Open AI ChatContinue a grounded conversation with the instrument in context.Advanced modulesOpen role- and entitlement-controlled portfolio and trading tools.
Validated OHLC

Interactive price chart

Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.

Open full workspace
Interactive price chartInteractive chart loads when this section is visible.
Auditable calculations

Daily technical summary

Calculated from validated daily candles. Descriptive research only.

Calculating technicals…
Intelligence: activity, structure and reported deals

Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.

Company derivatives · NSE

CONCORDBIO futures & options

Expiry structure, futures, option chains and contract research.

Snapshot · timestamp unavailable
No observations

No matching contracts have verified observations for this filter.

DIRECTION · ACTIVITY · DISCLOSURES

CONCORDBIO Intelligence

Stored price, volume, causal structure and reported deals for this stock.

Market map
Checking research access…

Volume and pressure are activity estimates, not net money inflow. Futures and options retain their separate observations above.

Company reporting

Financial statements

IND AS · INR crore

Metric202620252024
Total Liabilities Shareholders' Equity2,234.732,034.251,700.71
Accumulated Depreciation Total-361.98-290.43-240.15
Other Liabilities Total3.722.821.96
Common Stock Total10.4610.4610.46
Other Equity Total1.52Not availableNot available
Other Current Assets Total1.223.6912.74
Prepaid Expenses7.567.397.33
Total Assets2,234.732,034.251,700.71
Current Portof LT Debt/Capital Leases0.882.347.85
Additional Paid-In Capital81.9781.9781.97
Cash12.190.915.14
Total Equity2,018.981,812.721,526.65
Long Term Investments95.0534.763.05
Retained Earnings(Accumulated Deficit)1,925.031,720.281,434.21
Total Common Shares Outstanding10.4610.4610.46
Property/Plant/Equipment Total-Gross1,228.041,134.651,026.63
Tangible Book Valueper Share Common Eq192.82173.17145.9
Goodwill Net0.4Not availableNot available
Total Liabilities215.74221.53174.06
Total Debt2.322.979.74
Short Term Investments418.66334.53266.52
Cashand Short Term Investments430.85335.44281.67
Total Receivables Net479.02547.48378.89
Notes Payable/Short Term Debt000
Deferred Income Tax45.3634.0228.06
Accounts Receivable-Trade Net460.2521.65350.84
Property/Plant/Equipment Total-Net866.06844.22786.48
Minority Interest-3.85Not availableNot available
Total Current Liabilities169.08184.06142.16
Total Inventory331.47241.24215.61
Accounts Payable101.91113.0494.44
Other Currentliabilities Total66.2968.6839.77
Total Long Term Debt1.430.631.89
Intangibles Net1.421.120.32
Other Long Term Assets Total7.867.912.16
Note Receivable-Long Term13.831112.47
Total Current Assets1,250.111,135.24896.23
Capital Lease Obligations1.430.631.89
Accrued ExpensesNot available00.1
Long Term DebtNot available00
Fundamentals

Valuation and ratios

Valuation

PEG Ratio18.73

Price to Sale Ratio13.59

Growth

Debt 5Yr CAGR %-51.83

Margins

Operating Margin 12m28

Operating Margin 5y Avg33.91

Net Profit Margin 12m24.62

Net Profit Margin 5y27.99

Yield

Dividend Yield %0.55

Risk and consensus

Source-qualified signals

Risk metrics

Overall RiskBalanced risk

Board Risk42.14

Analyst consensus

ConsensusBuy

Consensus score2.25

Analyst opinions4

Strong Sell count0

Sell count0

Hold count2

Buy count1

Strong Buy count1

Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.
Industry context

Peer comparison

Only peers present in the company profile payload are displayed.

CompanyPriceMarket capP/EResearch
Sun Pharmaceutical IndustriesINR 1,9444.66 L38.4—
Divi's LaboratoriesINR 8,291.552.20 L73.32—
Torrent PharmaceuticalsINR 4,9651.89 L72.73—
CiplaINR 1,4751.19 L27.57—
Zydus LifesciencesINR 1,106.251.10 L21.19—
Shareholding

Ownership

Promoter
44.08%
FII
7.53%
MF
4.40%
Other
43.99%
Corporate actions

Events

  1. board MeetingsQuarterly Results
  2. annual General MeetingAGM
  3. dividendRs.7.5500 per share(755%)Final Dividend
  4. board MeetingsAudited Results & Final Dividend
  5. board MeetingsQuarterly Results
  6. board MeetingsQuarterly Results
  7. annual General MeetingAGM
  8. dividendRs.10.7000 per share(1070%)Final Dividend
  9. board MeetingsQuarterly Results
  10. board MeetingsAudited Results & Final Dividend
  11. board MeetingsQuarterly Results
  12. board MeetingsQuarterly Results
  13. board MeetingsQuarterly Results
  14. annual General MeetingAGM
  15. dividendRs.8.7500 per share(875%)Dividend
  16. board MeetingsAudited Results & Dividend
  17. board MeetingsQuarterly Results
  18. board MeetingsQuarterly Results
Rusaka Markets Community

Discussion and sentiment for Concord Biotech

Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.

Rusaka Markets Community

Community discussion loads as you approach this section.

Company profile

Business information

What the company does

Concord Biotech Limited is an India-based research and development-driven biopharmaceutical company focused on manufacturing fermentation-based active pharmaceutical ingredients (APIs) and formulations. The Company is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its product portfolio encompasses both biopharmaceutical APIs and formulations across various therapeutic areas, including immunosuppressants, oncology, anti-infectives, nephrology, and critical care. Its API products include Immunosuppressant, Oncology Drugs, Anti-bacterial, and others. Its Immunosuppressant include Tacrolimus, Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Sirolimus, Pimecrolimus, and Voclosporin. Its Oncology Drugs include Temsirolimus, Everolimus, Romidepsin, Mitomycin, Dactinomycin, Midostaurin, and Doxorubicin. Its Anti-bacterial include Mupirocin, Mupirocin Calcium, Teicoplanin, and others.

Company facts

Industry
Biotechnology & Drugs
Sector
Biotechnology & Drugs
NSE Code
CONCORDBIO
BSE Code
543960
Questions

Stock FAQ

What is the symbol and ISIN of Concord Biotech?

Concord Biotech has the symbol CONCORDBIO and ISIN - INE338H01029.

What is the latest recorded price of Concord Biotech?

The latest available recorded price of Concord Biotech is INR 1,374.70 as of 2026-08-06T20:57:09.266Z. This is a source-stamped snapshot, not a live quote.

What are the year high and year low of Concord Biotech?

Year high: INR 1,803.60. Year low: INR 987.05.

What is the market capitalization of Concord Biotech?

Market capitalization: INR 14,332.42 crore.

What is the P/E ratio of Concord Biotech?

P/E ratio: 48.66.

What is the dividend yield of Concord Biotech?

Dividend yield: 0.55%.

How is the financial performance of Concord Biotech based on revenue, net income, and EPS?

Revenue: INR 1,054.89 crore. Net income: INR 260.91 crore. EPS: INR 26.54.

What are the price-to-book and price-to-sales ratios of Concord Biotech?

Price-to-book ratio is unavailable in the current source. Price-to-sales ratio: 13.59.

Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.